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Non-typeable Haemophilus influenzae (NTHi) cause a range of illnesses including otitis
media, sinusitis, and exacerbation of chronic obstructive pulmonary disease, infections
that contribute to the problem of antibiotic resistance and are themselves often intractable
to standard antibiotic treatment regimens. We investigated a strategy to exploit binding
of the complement inhibitor Factor H (FH) to NTHi as a functional target for an
immunotherapeutic containing the NTHi binding domain of FH fused to the Fc domain
of IgG1. Chimeric proteins containing the regions that most FH-binding bacteria use to
engage human FH, domains 6 and 7 (FH6,7/Fc) and/or 18 through 20 (FH18–20/Fc),
were evaluated for binding to NTHi. FH6,7/Fc bound strongly to each of seven NTHi
clinical isolates tested and efficiently promoted complement-mediated killing by normal
human serum. FH18–20/Fc bound weakly to three of the strains but did not promote
complement dependent killing. Outer-membrane protein P5 has been implicated in FH
binding by NTHi, and FH6,7/Fc binding was greatly diminished in five of seven P5
deficient isogenic mutant strains tested, implicating an alternative FH binding protein in
some strains. Binding of FH18–20/Fc was decreased in the P5 mutant of one strain.
A murine model was used to evaluate potential therapeutic application of FH6,7/Fc.
FH6,7/Fc efficiently promoted binding of C3 to NTHi exposed to mouse serum, and
intranasal delivery of FH6,7/Fc resulted in significantly enhanced clearance of NTHi
from the lung. Moreover, a P5 deficient mutant was attenuated for survival in the lung
model, suggesting that escape mutants lacking P5 would be less likely to replace
strains susceptible to FH6,7/Fc. These results provide evidence for the potential utility
of FH6,7/Fc as a therapeutic against NTHi lung infection. FH binding is a common
property of many respiratory tract pathogens and FH/Fc chimeras may represent
promising alternative or adjunctive therapeutics against such infections, which are often
polymicrobial.
Keywords: factor H, non-typeable Haemophilus influenzae, complement, P5, outer-membrane protein, lung
infection
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INTRODUCTION
Non-typeable Haemophilus influenzae (NTHi), a common cause
of respiratory tract infections, is associated with otitis media and
sinusitis in children, and exacerbations of chronic obstructive
lung disease (COPD; Murphy et al., 2009; Sethi et al., 2016).
NTHi is consistently found in the lower respiratory tract in
30% of COPD cases and recurrent infection by diverse NTHi
strains results in exacerbation of this disease (Murphy and
Sethi, 2002), which aﬄicts greater than 6% of adults and has
been ranked the third leading cause of death in the U.S.
(Centers for Disease Control and Prevention [CDC], 2012).
Nasopharyngeal colonization with NTHi in infants predisposes
to recurrent otitis media (Harabuchi et al., 1994) in which
NTHi has recently emerged as the most frequent bacterial isolate
(Kaur et al., 2013). NTHi can also cause invasive infections
including bacteremia, pneumonia, and meningitis, especially in
neonates and individuals that are immunocompromised or have
comorbidities (Van Eldere et al., 2014; Collins et al., 2016). Otitis
media is the leading cause of pediatric antibiotic prescription,
with β-lactams representing the frontline therapeutics (McCaig
et al., 2002; Grijalva et al., 2009). The spread of β-lactamase
producing NTHi as well as β-lactamase-negative ampicillin
resistant strains globally has led to use of broader spectrum
agents with their attendant complications (Van Eldere et al.,
2014). Whereas, vaccination has been effective against type b
H. influenzae with implementation of the capsular conjugate
vaccine (Ladhani, 2012), it is complicated in NTHi, which lack
capsule and exhibit extensive antigenic diversity of immunogenic
outer-membrane proteins among strains (Gilsdorf, 1998). The
highly conserved NTHi protein D has been included in the
pneumococcal PhiD-CV (Synflorix; GSK) vaccine, which has
shown moderate efficacy against otitis media in clinical studies.
However, PhiD-CV has not been evaluated for other conditions
such as exacerbation of COPD. Moreover, a recent study in a
murine lung model was unable to demonstrate protection against
NTHi after immunization with PhiD-CV (Siggins et al., 2015).
New non-antibiotic anti-infectives active against NTHi would be
beneficial as primary or adjunctive therapies.
To survive in their mammalian hosts, pathogens possess
multiple countermeasures against innate immune defenses, in
which the complement system plays a major role (Ram et al.,
2010). One strategy shared by NTHi and many medically
important microbes is to bind to human complement inhibitors,
including Factor H (FH), vitronectin, and C4b-binding protein,
to dampen complement activation on their surfaces (Würzner,
1999; Kraiczy and Würzner, 2006; Blom et al., 2009). FH inhibits
the alternative pathway of complement by serving as a cofactor
for the factor I-mediated cleavage of C3b to the hemolytically
inactive iC3b fragment (Pangburn et al., 1977). FH also causes
“decay acceleration,” whereby it irreversibly dissociates the Bb
fragment from the alternative pathway C3 convertase, C3bBb
(Weiler et al., 1976; Whaley and Ruddy, 1976; Fearon and
Austen, 1977). FH comprises 20 domains, also known as short
consensus repeat domains (SCRs) or complement control protein
domains (CCPs) that are arranged in the form of a single chain
(Ripoche et al., 1988). The first four N-terminal domains are
necessary and sufficient for complement inhibition (Sharma and
Pangburn, 1996). Pathogens bind FH regions distinct from its
complement inhibitory domains, information that has been used
to engineer FH fusion proteins lacking complement-inhibitory
activity to the Fc region of IgG and thereby exploit this virulence
property as a therapeutic target to direct Fc mediated clearance
of Neisseria meningitidis and Neisseria gonorrhoeae in animal
models of infection (Shaughnessy et al., 2014, 2016). This
approach would be attractive for treatment of infections with
NTHi, which frequently cause disease in the context of co-
infection by other pathogens (Broides et al., 2009), primarily
involving Streptococcus pneumoniae, Moraxella catarrhalis, and
Streptococcus pyogenes, each of which expresses FH binding
proteins (Horstmann et al., 1988; Dave et al., 2001; Bernhard
et al., 2014).
Previous studies have shown that NTHi bind to FH (Hallström
et al., 2008), and that binding is mediated by the cell-surface
outer-membrane protein P5, a member of the OmpA family of
proteins, which contributes to resistance of NTHi to killing by
complement (Langereis et al., 2014; Rosadini et al., 2014). P5
has also been described as an adhesin interacting with epithelial
cells and mucosal surfaces via several potential binding partners
including respiratory mucin (Reddy et al., 1996), Eustachian tube
mucus (Miyamoto and Bakaletz, 1996), ICAM-1 (Avadhanula
et al., 2006), and CEACAM-1 (Hill et al., 2001), however its
role in interaction with CEACAM-1 was recently shown to be
indirect (Tchoupa et al., 2015). In addition to virulence related
phenotypes identified in vitro, P5 has been implicated in bacterial
colonization in the chinchilla (Sirakova et al., 1994) and lung
infection in mice (Wong et al., 2013; Euba et al., 2015). In this
study we identify the regions in FH that bind to NTHi, determine
the role of P5 in these interactions, and evaluate the ability of a
fusion protein that combines the NTHi-binding fragment of FH
with the Fc domain of IgG to mediate complement-dependent
killing of NTHi and facilitate clearance of bacteria in vivo in a
mouse lung model of NTHi infection.
MATERIALS AND METHODS
Media and Haemophilus influenzae Growth
Conditions
NTHi clinical isolates NT127 (Wong et al., 2011), Hi375 (Mell
et al., 2014), Hi486 (Hood et al., 1999), 86-028NP (Harrison
et al., 2005), PittGG (Buchinsky et al., 2007), R2846 (Barenkamp
and Leininger, 1992), and R2866 (Nizet et al., 1996; Erwin
et al., 2005) were grown at 35 ± 1.5◦C in Brain Heart Infusion
supplemented with 10 µg/ml nicotinamide adenine dinucleotide
(NAD) and 10 µg/ml hemin (sBHI) on agar plates or in
sBHI broth. DNA was transformed into naturally competent
H. influenzae prepared as described (Barcak et al., 1991).
Gentamicin (Gm) and 3,4-cyclohexenoesculetin-β-D-galacto-
pyranoside (S-gal, Sigma-Aldrich), and D-xylose were added to
sBHI at 10 µg/ml, 300 mg/L, and 1mM, respectively. FH/Fc
binding, C3 deposition and serum bactericidal assays were
performed on NTHi grown on chocolate agar plates as described
below.
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Bacterial Strains and Mutants
1P5 deletion mutations in Hi375, Hi486, PittGG, 86-028NP,
R2846, and R2866 were created by transformation of a ∼3
kb PCR product amplified with primers 5 omp1 and 3 omp2
from H. influenzae Rd strain RP5G (Rosadini et al., 2014). The
NT127 P5 deletion mutant complemented with the wildtype
gene from NT127 at the xyl locus, NTP5X, or carrying empty
vector sequences at the xyl locus, NTP5V, have been described
previously (Rosadini et al., 2014). The allelic exchange PCR
product for deletions contains a replacement of the P5 coding
region with the aacC1 gentamicin (Gm) resistance cassette
and flanking regions for homologous recombination. GmR
transformants were selected on sBHI agar containing Gm.
All strain constructions were verified by PCR amplification
across the inserted recombinant region with primers specific for
flanking sequences not contained in sequences within the P5
knockout exchange delivery DNA and by PCR amplification to
verify presence of the gentamicin resistance cassette with aacC1 5′
(ATGTTACGCAGCAGCAACGATGTTACGCAGCAGG) and 3′
(TTAGGTGGCGGTACTTGGGTCGAT) primers to the coding
region. Strains were additionally verified via Coomassie Brilliant
Blue staining of whole-cell lysates after SDS-PAGE, and all
mutants were deficient in an ∼37–39 kDa band present in the
wild-type parents consistent with the predicted sizes of the
corresponding P5 proteins (Figure S1).
Complement
Human serum was obtained from normal healthy adult
volunteers who provided informed consent. Participation was
approved by the University ofMassachusetts Institutional Review
Board for the protection of human subjects. Serum was obtained
by allowing blood to clot at 25◦C for 30min followed by
centrifugation at 1500 g for 20min at 4◦C. To study the effects
of the FH/Fc proteins without confounding by natural anti-NTHi
antibodies present in NHS, we depleted IgG and IgM from freshly
collected human serum, as described previously (Ray et al.,
2011). Briefly, EDTA (final concentration 10mM) andNaCl (final
concentration 1M) were added to freshly prepared human serum
and treated sera was passed first over anti-human IgM agarose
(Sigma), followed by passage through protein G-Sepharose; both
columns were equilibrated in PBS containing 10mM EDTA and
1M NaCl. NaCl was added to minimize C1q depletion during
passage of serum through the anti-human IgM column. The flow-
through was collected, spin concentrated and dialyzed against
PBS/0.1mM EDTA to its original volume using a 10-kDa cutoff
Amicon Ultra-15 centrifugal filter device (Millipore, Bedford,
MA), sterilized by passage through a 0.22-µm filter (Millipore),
aliquoted and stored at−70◦C. Hemolytic activity was confirmed
using a total complement hemolytic plate assay (The Binding
Site Inc., Birmingham, U.K). Depletion of IgG and IgM was
confirmed by dot-blot assays. In some experiments, complement
activity of serum was destroyed by heating serum at 56◦C for 1 h.
Mouse complement was obtained by allowing blood obtained by
terminal cardiac puncture to clot for 20min at room temperature
followed by incubation for 20min on ice. Serum was collected
after centrifugation at 10,000 g for 10min at 4◦C and stored in
single-use aliquots at −80◦C. This procedure was performed in
accordance with approved IACUC protocols at the University of
Massachusetts Medical School.
FH/Fc Fusion Proteins
Cloning, expression and purification of a chimeric protein
comprising human FH domains 18–20 fused to human IgG1
Fc (FH18–20/Fc) and FH domains 6 and 7 fused to human
IgG1 Fc (FH6,7/Fc) have been described previously (Shaughnessy
et al., 2011, 2014). Plasmids encoding the FH/Fc fusion proteins
were used to transiently transfect CHO cells using lipofectin
(Life Technologies), according to themanufacturer’s instructions.
Media from transfected cells was collected after 2 days and
FH/Fc was purified by passage over protein A agarose. Mass was
determined by Coomassie Blue staining of proteins separated by
SDS-PAGE and protein concentrations were determined using
the BCA protein Assay kit (Pierce).
Antibodies
Anti-human IgG FITC (Sigma), anti-humanC3c-FITC (BioRad),
and anti-mouse C3 FITC (MP Biomedicals) were used in flow
cytometry assays, all at a dilution of 1:100 in Hanks Balanced
Salt Solution (HBSS) containing 0.1% BSA and 1mM CaCl2 and
1mMMgCl2 (HBSS
++/BSA).
Flow Cytometry
Binding of FH/Fc fusion proteins to bacteria and human
and mouse C3 deposition on NTHi were performed by flow
cytometry as described previously (Shaughnessy et al., 2011,
2014; Rosadini et al., 2014). All incubations with proteins, serum
and Ab were carried out in HBSS++/BSA. Data were acquired on
a BD FACSCalibur flow cytometer and data were analyzed using
FlowJo software.
Serum Bactericidal Assays
NTHi harvested from chocolate agar plates following overnight
growth were repassaged onto fresh chocolate agar plates and
grown for 5 h at 37◦C in an atmosphere containing 5%
CO2. Bacteria were resuspended in HBSS
++/BSA. The reaction
mixture contained 20% human complement and ∼1000 CFU
of NTHi and the indicated concentrations of FH/Fc in a final
volume of 75µl. Aliquots of 12.5µl reactionmixtures were plated
onto chocolate agar in duplicate at the beginning of the assay (t0)
and again after incubation at 37◦C for 30min (t30). Survival was
calculated as the number of viable colonies at t30 relative to t0.
H. influenzae Competition and FH
Protection Assays in the Murine Lung
Model
H. influenzae grown to mid-log phase (OD600 0.3–0.5) in
5 ml sBHI were pelleted, resuspended at the appropriate
concentrations inHank’s balance salt solution containing calcium
andmagnesium chloride, and inoculated (40µl) intranasally into
the nares of 6–8 week-old female C57BL/6 mice (Charles River
Laboratories, Wilmington, MA) anesthetized with ketamine
(50mg/kg) and xylazine (5mg/kg) by intraperitoneal (IP)
injection. Lungs were harvested and homogenized in 2ml of BHI
at 20 h post-bacterial inoculation and plated onto sBHI agar (with
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FIGURE 1 | NTHi NT127 P5 binds FH domains 6 and 7. NT127, P5
deletion mutant NTP5V, (1P5), and the complemented P5 deletion mutant
NTP5X, (1P5/comp) were incubated with 10 µg/ml of FH6,7/Fc (left graph), or
FH18–20/Fc (right graph) and bound FH/Fc was detected with anti-human IgG
FITC. “Control” represents the wild-type strain incubated with anti-human IgG
FITC (no added FH/Fc). Numbers alongside the histograms indicate the
median fluorescence intensity of the entire bacterial population; the
outline/shading of each value corresponds to that used for the histogram.
X-axis, fluorescence on a log10 scale; Y-axis, counts. One representative
experiment of two reproducible repeats is shown.
S-gal and D-xylose for the in vivo competition assay experiments)
and grown for colony forming unit (CFU) determination.
For in vivo competition assays to assess virulence of the
1P5 mutant relative to virulence of the wild-type, 107 CFU of
NTHi NT127 containing empty cloning vector, NTV, (parent),
1P5 mutant containing empty vector, NTP5V (1P5), and
1P5 mutant with complementing copy of P5 in trans, NTP5X
(P5 complemented; Rosadini et al., 2014) were co-inoculated
intranasally with an equal number of an H. influenzae LacZ+
expressing competitor strain (Rosadini et al., 2011) into the nares
of mice (n = 5). Ratio of CFU of the experimental strain (white
colonies, LacZ−) to competitor strain (black colonies, LacZ+)
was reported as the competitive index.
For protection assays with FH6,7 human IgG1 Fc fusion
protein (FH6,7/HuFc; Shaughnessy et al., 2014) 107 CFU NT127
wild-type was co-inoculated with 50 µg of protein intranasally
into mice (n = 10 for FH6,7/HuFc group; 8 for PBS control
group), and bacterial CFU recovered from lungs as above.
Experiments were conducted with approval and in accordance
with guidelines of the Institutional Animal Care and Use
Committee at the University of Mississippi Medical Center
(Jackson, MS).
RESULTS
P5 on NTHi NT127 Interacts with FH
Domains 6 and 7
Most microbes that bind human FH interact with a region
spanned by FH domains 6 and 7 and/or 18 through 20. We
therefore examined binding of two FH/Fc fusion proteins,
FH6,7/Fc and FH18–20/Fc that spanned these common
microbial binding regions in FH, to NTHi strain NT127. To
verify that P5 was indeed the molecule that interacted with the
FH fragments, we compared wild-type to a P5 deletion mutant
(1P5) and a complemented strain (1P5/comp). As shown in
Figure 1, the wild-type strain bound FH6,7/Fc strongly, but
barely bound FH18–20/Fc. Loss of P5 almost totally abrogated
FIGURE 2 | FH6,7/human Fc mediates human C3 deposition and
complement-dependent killing of NTHi NT127. (A) FH6,7/Fc enhances
C3 deposition on NT127. Wild-type strain NT127 (127 WT; left graph) and 127
1P5 (right graph) were incubated with human complement (C) alone, or C plus
either FH6,7/Fc or FH18–20/Fc, each at a concentration of 20 µg/ml.
Following incubation at 37◦C for 30min, C3 deposited on bacteria was
measured by flow cytometry. “Control” represents the wild-type strain
incubated in buffer alone (no C added). X-axis; fluorescence on a log10 scale;
Y-axis, counts. Numbers alongside the histograms indicate the median
fluorescence intensity of the entire bacterial population; the outline/shading of
each value corresponds to that used for the histogram. One representative
experiment of two reproducible repeats is shown. (B) FH6,7/Fc enhances
C-dependent killing of NTHi NT127. Strain NT127 and its 1P5 mutant were
incubated with 20% C alone, or 20% C plus either FH6,7/Fc or FH18–20/Fc
each at a final concentration of 20 µg/ml, and percent survival of bacteria
(shown on the Y-axis) was measured in a serum bactericidal assay. Each bar
represents the mean (range) of two separate experiment. ANOVA was used to
compare the survival of each strain under the three incubation conditions. *P <
0.05; **P < 0.01.
binding of FH6,7/Fc, which was restored with complementation.
A dose response binding assay revealed that near maximal
binding of FH6,7/Fc was achieved at 20 µg/ml (Figure S2). These
data suggest that P5 on NT127 interacts with FH domains 6
and 7.
FH6,7/Fc Enhances Complement
Deposition on and Killing of NTHi NT127
Because several medically important microbes bind to similar
regions in FH, FH fragments fused to Fc have the potential to
serve as anti-bacterial immunotherapeutics. We asked whether
FH6,7/Fc could activate complement on NTHi NT127. As shown
in Figure 2A, FH6,7/Fc enhanced C3 fragment deposition on
the wild-type strain (gray histogram in the left panel) relative
to C3 deposited on bacteria incubated either with complement
alone (solid line) or complement plus the control protein FH18–
20/Fc that bound only weakly to strain NT127 (dashed line).
Compared to the wild-type strain, the P5 deletionmutant showed
a smaller increase in C3 deposition in the presence of the FH/Fc’s
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FIGURE 3 | Binding of FH6,7/Fc (upper panel) and FH18–20/Fc (lower panel) to six additional NTHi isolates and their P5 deletion mutants (1P5). Flow
cytometry to measure the amount of binding of the two FH/Fc fusion molecules was carried out as described in Figure 1. Axes are as described in Figure 1.
Numbers alongside the histograms indicate the median fluorescence intensity of the entire bacterial population; the number in the shaded box represents binding to
the wild-type strain. Control reactions represent wild-type bacteria incubated with anti-human IgG FITC (no FH/Fc added). The median fluorescence for the controls
was ∼5 and has not been indicated in the figure for simplicity.
and the C3 deposition histograms in the presence of both FH/Fc
molecules were similar.
To determine whether FH6,7/Fc could affect killing of NT127,
bacteria were incubated with either complement alone, or
complement plus each of the FH/Fc’s (each at 20 µg/ml).
Exposure to FH6,7/Fc in the presence of complement resulted
in killing of the wild-type strain (Figure 2B), whereas survival
of the 1P5 mutant was not affected under this condition. No
killing of either strain was observed with complement alone, or
complement plus FH18–20/Fc.
FH6,7/Fc Mediates Killing of Six Additional
Clinical NTHi Isolates
To ascertain that binding and activity of FH6,7/Fc was not
restricted to a single NTHi isolate, we studied six additional
NTHi strains and their1P5 mutants. All wild-type NTHi strains
bound FH6,7/Fc (Figure 3; gray shaded histograms in the upper
panel). Rather surprisingly, the P5 deletion mutants of two
isolates, 375 and PittG, continued to bind FH6,7/Fc, suggesting
that these strains could bind to FH domains 6 and 7 through a
molecule distinct from P5. It is worth noting that the P5 deletion
mutant of 375 showed an increase in FH6,7/Fc binding compared
to the parent strain (1.7- and 1.4-fold increase in fluorescence in
two experiments performed).
Binding of FH18–20/Fc showed varying patterns. Similar
to findings with strain NT127, strains 486 and PittGG bound
minimal amounts of FH18–20/Fc. The four other strains (375,
86-028NP, R2846, and R2866) bound FH18–20/Fc to varying
degrees, with maximum binding seen to strain R2846 and
the lowest binding seen with R2866. However, the amount of
binding noted was∼10- to∼50-fold less than the corresponding
FH6,7/Fc binding. Deleting P5 decreased FH18–20/Fc binding to
R2846, suggesting that P5 expressed by this strain could interact
with the C-terminus of FH. As observed with FH6,7/Fc, a small
increase in FH18–20/Fc binding to the 1P5 mutant of 375 was
detected.
The ability of the FH/Fc’s to mediate complement-dependent
killing of the NTHi isolates was next examined. As shown in
Figure 4, all six wild-type isolates showed <50% survival in the
presence of FH6,7/Fc and complement. Consistent with their
ability to bind high amounts of FH6,7/Fc, the 1P5 mutants
of 375 and PittGG were also killed. None of the isolates were
killed by FH18–20/Fc. Of note, the P5 deletion mutant of 2846
showed >50% killing with complement alone, and addition of
either FH/Fc molecule had no further effect on survival.
Taken together, the data suggest that FH6,7/Fc binds to all
NTHi strains tested. In some strains, FH domains 6 and 7 interact
with a molecule on NTHi distinct from P5. FH6,7/Fc canmediate
complement-dependent killing of all tested strains.
Activity of FH6,7/Fc in a Mouse Model of
NTHi Lung Infection
As a prelude to testing the efficacy of FH6,7/Fc in vivo, its ability
to deposit mouse complement on NTHi was tested. As shown
in Figure 5A, FH6,7/Fc was capable of mediating mouse C3
deposition (gray shaded histogram in the left graph) consistent
with results with human complement (Figure 1). Similarly,
deposition of mouse C3 mediated by FH6,7/Fc was abrogated
in the 1P5 mutant, and that mediated by FH18–20/Fc slightly
increased.
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FIGURE 4 | Bactericidal activity of FH6,7/Fc against NTHi and their P5 deletion mutants. Serum bactericidal assays were performed using 20% human
complement either alone (C) or in the presence 10 µg/ml of FH6,7/Fc or FH18–20/Fc. Survival of bacteria at 30min relative to baseline CFU at the start of the assay is
shown on the Y-axis. The mean (range) of two separate experiments is shown. Comparison of survival across the three reaction conditions for each strain was made
by ANOVA. *P < 0.05; **P < 0.01; ***P < 0.001.
While P5 has been implicated in virulence in the chinchilla
middle ear (Sirakova et al., 1994), it is possible that it is not
required for bacterial survival in the lung, which would provide
a means of escape from a FH6,7/Fc based therapeutic by strains
that lose P5 via mutation. Therefore, we evaluated the 1P5
mutant in the lung model. As shown in Figure 5B, survival of the
1P5 mutant was significantly attenuated, and complementation
restored survival that of the parent strain.
To evaluate the ability of FH6,7/Fc to reduce the burden of
NTHi infection, we utilized the mouse lung model. FH6,7/Fc
vs. PBS carrier alone was delivered intranasally concurrent with
NTHi NT127 inoculation and lungs harvested for bacterial CFU
determination after 20 h. ThemeanCFU ofNTHi recovered from
the lungs of FH6,7/Fc treated mice was 4.8-fold lower than that
of NTHi infected mice receiving carrier alone, and this difference
was statistically significant (Figure 5C).
DISCUSSION
In this report, we have defined domains 6 and 7 as a region in FH
that binds to all seven strains of NTHi studied. Five of the seven
strains bound FH domains 6 and 7 through P5. Deleting P5 from
two strains (375 and PittGG) did not decrease FH6,7/Fc binding,
suggesting that these strains bound FH through an alternate
molecule(s). The presence of a molecule on NTHi distinct from
P5 that bound FH was also suggested by Langereis et al. (2014),
who observed residual FH binding to the P5 deletion mutants of
two of the three NTHi strains that they evaluated. FH domains
18 through 20 also interacted with strains 375, 86-028NP, R2846
and to a lesser extent, strain R2866. P5 of strain R2846 bound
to FH domains 18–20, evidenced by the decrease in binding
noted upon deleting P5. Residual FH18–20/Fc binding to R2846
1P5 suggests the presence of an alternate FH ligand on this
strain. Unexpectedly, deletion of P5 in strain R2846 resulted in
sensitivity to complement even in the absence of FH/Fc fusion
proteins. It is possible that the R2846 1P5 mutant is more
susceptible, relative to other strains, either to the alternative
and/or lectin complement pathways. Another possibility is that
R2846 1P5 may be hypersensitive to residual IgM in antibody
depleted human serum; we showed previously that P5 expression
may facilitate evasion of the classical pathway by decreasing
binding of IgM to the bacterial surface (Rosadini et al., 2014).
Strain 86-028NP also showed evidence for two distinct molecules
that bound to FH; similar to R2846, the alternate ligand was
implicated in interacting with FH domains 18–20. Similar to the
two binding regions in FH observed for NTHi in this study,
Hallstrom and colleagues showed previously that H. influenzae
type b (Hib) strains also interacted with FH via a region spanned
by domains 6 and 7 and 18–20 (Hallström et al., 2008). Meri et al
further confirmed binding of the two C-terminal domains of FH
to H. influenzae (Meri et al., 2013). A ligand for FH on Hib was
subsequently identified by Fleury et al. as a lipoprotein that was
named protein H (PH; encoded by a gene called lph), which is not
present in NTHi strains (Fleury et al., 2014).
An interesting observation was the increase in binding of
both FH6,7/Fc and FH18–20/Fc upon deleting P5 from strain
375. Possible explanations for this observation include increased
expression of the alternate ligand for FH and/or increased
exposure of the FH binding regions of the alternate binding
site(s) when P5 is deleted. Collectively, these data suggest that the
interactions between the two major microbial binding regions in
FH and NTHi strains are complex and a summary of the binding
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FIGURE 5 | FH6,7/Fc mediates mouse C3 deposition on NTHi, targets a
structure required by NTHi during lung infection, and can decrease
burden of NTHi in the murine lung model. (A) FH6,7/Fc increases mouse
C3 deposition on NTHI NT127. Strain NT127 and its 1P5 mutant were
incubated with mouse complement (Mouse C) alone, or mouse complement in
the presence of 10 µg/ml of either FH6,7/Fc or FH18–20/Fc for 30min at
37◦C. Control reactions show the wild-type strain incubated in buffer alone
followed by anti-mouse C3 FITC. Mouse C3 deposited on bacteria was
measured by flow cytometry. Axes are as described in Figure 1. Numbers
alongside the histograms represent the median fluorescence of the entire
bacterial population and the shading/patterns associated with the numbers
correspond to that used for the histogram. One representative experiment of
two reproducible repeats is shown. (B) Loss of the FH6,7/Fc target protein P5
results in attenuation of NTHi survival in the mouse lung. Strain NT127, its 1P5
mutant, and the 1P5 complemented with wild-type P5 were each
co-inoculated intranasally with an equal number of a lacZ expressing NT127
derived reference strain into C57BL/6 mice. Lungs were harvested 20 h
post-inoculation for determination of bacterial CFU. Ratio of CFU recovered of
the experimental strain (LacZ−) to competitor strain (LacZ+) is reported as the
competitive index. Bars indicate means. Differences were statistically
significant between the 1P5 vs. the parent and complemented strains (*p <
0.01, ANOVA with Bonferroni’s multiple comparison test). (C) FH6,7/Fc
decreases burden of NTHi in the lung model. 107 CFU NTHi NT127 and 50 µg
of FH6,7/HuFc protein (control animals received PBS) were co-inoculated
intranasally into C57BL/6 mice and lung CFU determined at 20 h
post-inoculation. Bars, geometric means. Lower limit of detection, 200 CFU.
Statistical analysis was by Mann-Whitney. *P = 0.006.
data between the FH/Fc’s and the strains of NTHi used in this
study is provided in Table 1.
We have shown previously that FH/Fc fusion molecules
activate complement on the surface of N. meningitidis and N.
gonorrhoeae. FH6,7/Fc decreased the burden of meningococcal
bacteremia in infant Wistar rats (Shaughnessy et al., 2014) and
a derivative of FH18–20/Fc that contained a D→G mutation at
position 1119 in domain 19 decreased the burden of gonococcal
vaginal colonization in BALB/c mice (Shaughnessy et al., 2016).
Encouraged by these findings, we explored the ability of the
FH/Fc fusion proteins to mediate complement-dependent killing
of NTHi. Each of the seven NTHi strains tested were killed
(<50% survival) by FH6,7/Fc plus complement. The P5 deletion
mutants of 375 and PittG that also bound FH6,7/Fc were also
killed. Thus, targeting either P5 or the alternate receptor(s) by
TABLE 1 | Summary of interactions between FH and NTHi.
NTHi strain FH ligand(s) Binding region(s) in FH
NT127 P5 6,7
375 ? 6,7; 18–20
486 P5 6,7
PittGG ? 6,7
86-028NP P5 6,7
? 18–20
R2846 P5 6,7
? 18–20
R2866 P5 6,7
FH6,7/Fc results in complement-dependent killing. It is worth
noting that none of the strains showed killing over baseline
levels (complement alone) when FH18–20/Fc was present in the
reaction mixture. Lack of bactericidal activity of FH18–20/Fc is
likely because the density of Fc achieved on the bacterial surface
does not reach the threshold required to engage sufficient C1
complex to trigger C4 activation and subsequent downstream C3
deposition and membrane attack complex formation.
The C-terminus of FH plays an important role in regulation
of complement activation on host cell surfaces. The interactions
of domains 19 and 20 of FH interact with C3b fragments
and select glycosaminoglycans, respectively, rendering the cell
surface a complement non-activator (Kajander et al., 2011; Blaum
et al., 2015). The interaction of FH with sialic acid increases its
affinity for C3b and promotes the cofactor and decay accelerating
activities of FH (Fearon, 1978; Kazatchkine et al., 1979; Meri
and Pangburn, 1990). To overcome the potential concern of
FH18–20/Fc interfering with the function of endogenous FH,
we introduced a D→G mutation in domain 19 of FH18–20/Fc,
which abrogated hemolysis of anti-CD59-treated human RBC
by autologous serum (Shaughnessy et al., 2016). Although not
implicated in limiting complement activation on normal host
cells, FH domain 7 may play a critical role in certain pathological
conditions. Individuals with the 402H polymorphism in FH
domain 7 are at a higher risk for developing age-related macular
degeneration than persons with Y at position 402 (Haines et al.,
2005; Klein et al., 2005). Weismann and colleagues showed
that the 402H polymorphism decreased the affinity of FH for
malondialdehyde, a lipid peroxidation product that accumulates
in lesions of AMD called drusen (Weismann et al., 2011), thereby
enabling greater alternative pathway activation and hastening
ocular damage. We acknowledge that the development of FH/Fc
molecules as therapeutics should proceed with caution so as not
to interfere with the physiologic functions of FH. Further, studies
on the pharmacokinetics and stability of FH/Fc in vivo are also
important considerations in drug development.
P5 has been considered as a vaccine candidate against
NTHi, however the range of available immunogenic yet
conserved epitopes of this protein is limited by its antigenic
heterogeneity between strains. The approach of targeting a
functional interaction involved in pathogenesis may aid in
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bypassing this diversity. P5 may be an attractive target for
such novel therapeutics because this molecule is ubiquitously
expressed, is not phase-variable, and is not subject to epigenetic
regulation (Atack et al., 2015). Further, P5 deletion mutants show
reduced virulence in the chinchilla otitis media model andmouse
lung model compared to their wild-type counterparts (Sirakova
et al., 1994), which we have substantiated in the mouse lung
model with isogenic strains and complementation of the mutant
by restoration of wildtype P5 at an ectopic chromosomal location
(Figure 5B). Resistance to FH6,7/Fc, if this were to occur, would
require selection of P5 deletion mutants or P5 mutants that lack
the ability to bind to human FH, both of which may place the
bacterium at a fitness disadvantage as indicated by attenuation
of survival of NTHi in the lung model conferred by deletion of
P5. Alternatively, it is possible that mutational loss of FH binding
by P5 may not strongly influence the course of infection if, for
example, other P5 virulence phenotypes mediated by P5 exhibit
predominant effects and do not require the same structural
regions. Langeries et al. have identified the predicted surface
exposed loops 1 and 2 in P5 of NTHi strain R2866 as the FH
interacting regions (Langereis et al., 2014), and it is possible
that the surface exposed loops 3 and 4 of P5 mediate alternative
functions during infection. It will be of interest to determine
whether the role of P5 proteins in virulence vs. FH binding can be
dissociated. Identification of the alternate acceptor molecule(s)
for FH6,7/Fc also merits further consideration.
As an initial test of the potential therapeutic utility of FH6,7/Fc
against NTHi we evaluated its ability to decrease survival of
NTHi in a mouse model. Murine C3 was efficiently targeted
by FH6,7/Fc to the bacterial surface in the presence of mouse
serum in vitro, similar to human C3 (Figure 5A), suggesting
feasibility. Encouragingly, when delivered intranasally into the
lung, FH6,7/Fc was able to reduce the burden of NTHi compared
to mock treatment, producing a statistically significant 4.8-fold
decrease in recovered bacteria 20 h after inoculation (Figure 5C).
We note that this was a partial effect, and eradication of an
ongoing infection will likely require repeated doses. In addition,
clinical application would likely require aerosolization of the
fusion protein to achieve similar exposure to the bacteria,
however this delivery method is well-tolerated in patients treated
for other conditions and is a clinically feasible approach.We have
provided evidence for the efficacy of FH6,7/Fc in vivo, however,
we acknowledge that further work will be needed to define its
efficacy against NTHi infection in other niches such as themiddle
ear, sinuses, and the bloodstream. Further, only human but not
mouse FH has been reported to bind to NTHi (Langereis et al.,
2014). Thus, the efficacy of FH6,7/Fc in vivo in the presence of
human complement inhibitors that may counteract the efficacy
of the therapeutic merits study. Nevertheless, enhanced C3
deposition and killing of NTHi by FH6,7/Fc in human serum that
contains endogenous FH provides optimism for activity of this
molecule in the context of human complement.
In conclusion, FH6,7/Fc may prove a novel and promising
adjunctive therapeutic against NTHi infections, particularly in
instances of recurrent or recalcitrant infections, where multiple
courses of antibiotics have proven ineffective or only partially
effective and may be associated with adverse side effects.
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